Literature DB >> 19626672

Nature of "Tau" immunoreactivity in normal myonuclei and inclusion body myositis.

Mohammad Salajegheh1, Jack L Pinkus, Remedios Nazareno, Anthony A Amato, Kenneth C Parker, Steven A Greenberg.   

Abstract

Sarcoplasmic accumulation of phosphorylated-tau has been widely stated to occur in and contribute to the pathogenesis of muscle disease in inclusion body myositis. Twenty inflammatory myopathy and 10 normal muscle samples along with a range of other tissues were stained with anti-"tau" antibodies (tau-5, pS422, and SMI-31). Myonuclear and sarcoplasmic fractions were prepared using differential solubilization and laser-capture microdissection, and immunoblots were performed using pS422 and SMI-31 antibodies. All three antibodies demonstrated anti-tau immunoreactivity in myonuclei from normal and diseased muscle, but not in nuclei from other tissues. Western blots showed pS422 and SMI-31 immunoreactivity against nuclear proteins outside the region expected for phosphorylated-tau. Antibodies previously reported to indicate abnormal accumulation of phosphorylated-tau in IBM myofibers react to normal myonuclei and recognize proteins other than tau. Normal myonuclei contain neurofilament H or other unidentified 200 kDa proteins with similar phosphorylated motifs accounting for SMI-31 immunoreactivity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19626672     DOI: 10.1002/mus.21471

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  7 in total

Review 1.  The role of mitochondria in neurodegenerative diseases.

Authors:  Massimiliano Filosto; Mauro Scarpelli; Maria Sofia Cotelli; Valentina Vielmi; Alice Todeschini; Valeria Gregorelli; Paola Tonin; Giuliano Tomelleri; Alessandro Padovani
Journal:  J Neurol       Date:  2011-05-22       Impact factor: 4.849

Review 2.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

Review 3.  Loss of motor function in preclinical Alzheimer's disease.

Authors:  Aron S Buchman; David A Bennett
Journal:  Expert Rev Neurother       Date:  2011-05       Impact factor: 4.618

Review 4.  Sporadic inclusion body myositis: possible pathogenesis inferred from biomarkers.

Authors:  Conrad C Weihl; Alan Pestronk
Journal:  Curr Opin Neurol       Date:  2010-10       Impact factor: 5.710

Review 5.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

Review 6.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

Review 7.  Theories of the pathogenesis of inclusion body myositis.

Authors:  Steven A Greenberg
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.686

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.